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Chronic pancreatitis is an inﬂammatory disease of the pancreas that causes permanent changes in the function and structure
of the pancreas. It is most commonly a complication of cystic ﬁbrosis or due to a genetic predisposition. Chronic pancreatitis
generallypresentssymptomaticallyasrecurrentabdominalpain,whichbecomespersistentovertime.Thepaineventuallybecomes
disabling. Once speciﬁc medical treatments and endoscopic interventions are no longer eﬃcacious, total pancreatectomy is the
alternative of choice for helping the patient achieve pain control. While daily administrations of digestive enzymes cannot be
avoided,insulin-dependentdiabetescanbepreventedbytransplantingtheisolatedpancreaticisletsbacktothepatient.Thegreater
the number of islets infused, the greater the chance to prevent or at least control the eﬀects of surgical diabetes. We present here a
technical approach for the isolation and preservation of the islets proven to be eﬃcient to obtain high numbers of islets, favoring
the successful treatment of young patients.
1.Introduction
Pancreatitis is an inﬂammatory disorder of the pancreas that
can be acute or chronic. Acute pancreatitis is an “event”
whereas chronic pancreatitis is a “process” [1]. Acute pan-
creatitis occurs suddenly and resolves without signiﬁcant
irreversible damage to the gland. Chronic pancreatitis (CP)
can be considered the result of repeated acute inﬂammatory
events of varying duration. The long-standing inﬂammatory
injuries produce chronic inﬂammatory inﬁltrates, loss of
normal pancreatic cells and ﬁbrosis. In children, environ-
mental factors seem to play a smaller role in the etiology of
chronic pancreatitis than found in adults [2]. A large per-
centage of children with CP are still considered to have idio-
pathic disease. A signiﬁcant fraction has congenital anoma-
lies of the biliary tree, pancreas, stomach, or duodenum.
More than half of children with CP have mutations in the
genes encoding the cystic ﬁbrosis transmembrane conduct-
ance regulator (CFTR), cationic trypsinogen (PRSS1) or
serine protease inhibitor Kazal type 1 (SPINK1) [3–5].2 Journal of Transplantation
Mutations in CFTR and SPINK1 produce sporadic disease,
whereas mutations in PRSS1 result in autosomal dominant
hereditary pancreatitis [1]. Mutations in SPINK1 increase
the risk of chronic pancreatitis, and are considered disease
modiﬁers. Speciﬁc CFTR genotypes are signiﬁcantly asso-
ciated with pancreatitis but the pathogenesis is complex,
and other genes likely modify the risk [6]. For instance, the
combination of mutations in CFTR and SPINK1 increases
the risk of CP to around 900-fold, much higher than the risk
of a mutation in either gene alone [1].
The most evident symptom of CP is recurrent or chronic
abdominal pain. This pain can be so debilitating that
children are unable to attend school or perform any normal
activity due to frequent hospitalizations. Growing up under
suchconditionsmayleadtodepression,andthecombination
of the pain and depression frequentlyresults in a dependence
on narcotic analgesics [7, 8]. Once medical treatments are
no longer eﬃcacious, the only possible solution is surgical
treatment. Surgical options to treat CP depend on etiology
and the morphologic consequences of the disease. Some
patients are candidates for endoscopic pancreatic ductal
drainage, and others for resection treating a focal disease.
T o t a lp a n c r e a t e c t o m yi sr e s e r v e df o rd i ﬀuse changes, where
noothersurgicaloptionsarereasonable.Besidesthelife-long
need for substituting the exocrine function of the pancreas,
the endocrine function is also lost.
To reduce the severe consequences of the complete
removal of the pancreas and to save part of the endocrine
function at least for a time, the isolated islets of Langerhans
can be returned to the patient by injecting them into the
portal vein, so that they will eventually make their “home” in
the sinusoids of the liver [9, 10]. Isolation of islets from the
pancreas of young individuals is technically challenging even
when dealing with healthy donor organs. The concern of
producing an adequate yield of islets from pancreata aﬀected
byCPhasbeenoneofthelimitingfactorsinundertakingthis
procedure [11].
Our center has developed a successful method for the
isolation of islets from juvenile pancreatic organs derived
from deceased organ donors [12] and has applied it, with
some modiﬁcations, to pancreata excised from CP patients
to allow autologous islet transplantation.
Hereby, we describe the technical approach and the
results of the isolation of islets from the ﬁrst 10 young CP
patients who also received them back as autotransplants.
2.MaterialsandMethods
2.1. Islet Isolation. Total pancreaticoduodenectomy has been
performed with subsequent islet processing from pediatric
patients with CP at the Children’s Hospital of Pittsburgh
of UPMC and the Cleveland Clinic since 2009 (Table 1).
Once harvested, pancreata were immediately transferred in
cold preservation ﬂuid (HTK) to our laboratory with cold
ischemia time ranging between 30 minutes and 4 hours.
The method for islet isolation is a modiﬁcation of the
one that our group developed [13] and further adapted to
pediatric pancreata [12]. Brieﬂy, after the removal of fat,
Table 1: Patient age—patient body weight—pancreas weight.
Case no. Patient age (Yr) Patient Wt. (Kg) Pancreas Wt. (g)
1 18 115 89
21 8 7 7 9 2
3 9 34 29
41 1 4 2 4 0
5 15 86 189
61 6 5 6 5 9
71 8 4 3 4 1
8 15 74 101
91 5 4 5 4 8
10 10 49 76
connective tissue, and blood vessels, the pancreas is washed
in a cocktail of antibiotics, weighed and cut at the level
of the neck to access the pancreatic duct. Catheters are
placed in both sides of the transected duct, one catheter
towards the head, and the second towards the body, both
secured with suture. The diameter of the pancreatic ducts
can vary; however, in pancreata with CP, it is commonly
dilated. An appropriate catheter size is required to prevent
the leakage of digestive enzyme solution; usually it is never
smaller than 16–18G in diameter. A blend of exogenous
enzymesincludingcollagenasesandneutralproteases(Serva,
GMP grade, Heidelberg, Germany), freshly dissolved in
HBSS (Mediatech-Cellgro, Inc., Manassas VA, USA), is
prewarmed to 28–30◦C and introduced intraductally in a
special apparatus that Dr. Ray Rajotte (University of Alberta)
designed to allow for controlled continuous infusion of
enzymes in the pancreas at given temperatures. Infusion
of enzymes usually distends the pancreas and increases
its volume quite substantially; however, in CP, due to the
intrinsic features and ﬁbrosis, often only a limited distension
is obtained. The pancreatic organ is then transferred to the
Ricordi digestion chamber where a solution containing the
same enzyme blend circulates, while shaking is performed to
produce the mechanical disruption of the pancreatic tissue
[14].
In order to monitor the eﬀective digestion of the
pancreatic tissue, samples are obtained from the chamber
and monitored every 2–4 minutes. To analyze them, the
samples are suspended in a solution of HBSS containing
Dithizone (DTZ), a dye that colors the islets in red to
distinguish them from unlabeled exocrine and ductal tissue
[15]. When islets free of exocrine tissue are visible, the circuit
is then opened, and the tissue is collected in conical tubes.
As described previously [13], our group has developed a
method that allows, on one hand, to remove the islets from
the circuit as soon as they are free and, on the other, to
reinsert the enzymes back into the circuit itself to continue
the digestion of yet undisrupted tissue.
Once the digestion is completed and the isolated islets
and pancreatic cells are obtained, several washes in cold
RPMIsupplementedwithhumanserumalbumin(2.5%total
volume) are carried out. The cell pellet size is measured,
and a decision is made whether to use a cell separatorJournal of Transplantation 3
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Figure 1: Islet yield expressed as islet equivalent numbers.
IEQ per gram of digested pancreas
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Figure 2: Islet yield expressed as islet equivalent numbers per gram
of pancreatic tissue actually digested.
(Cobe 2991, Gambro BCT, Lakehood, CO, USA) to purify
and concentrate the islets, or to begin preparing the cells
for infusion. In adults, the pellet size cutoﬀ for further
puriﬁcation is 15mL. For pediatric patients, we follow the
guidelines deﬁned by the Minnesota group [16] that suggest
a maximum of 0.2mL/Kg body weight but never more
than the 15mL limit. This value dictates the choice for
the puriﬁcation step. Islets are delivered to the patient by
slow infusion into the portal vein resuspended in infusion
medium: CMRL 1066 medium (Mediatech) supplemented
with human serum albumin (5%), heparin (10u/Kg recip-
ient body weight), and ciproﬂoxacin (2μg/mL). Each 5mL
of cell pellet is resuspended in 200mL of infusion medium,
which makes up the content of one infusion bag (blood
transfusion bags, Fenwal, Lake Zurich, IL, USA). Up to three
bags, corresponding to 600mL and a maximum of 15mL of
cell pellet may be infused.
2.2. Islet Quantiﬁcation and Quality Control Testing. Islet
yield is determined by direct count of the islets stained with
DTZ, converting the diﬀerent islet sizes into islet equivalent
numbers (IEQ) [14]. An islet equivalent is equal to the vol-
ume of an islet with 150μm diameter. Viability is evaluated
prior to islet transplantation by trypan blue exclusion assay
or by a dual ﬂuorescence method with calcein AM and
propidium iodide [17]. Samples of the islet cells as well as
of the procurement ﬂuid (the ﬂuid in which the pancreas
is preserved until isolation) are analyzed by Gram stain,
andsterilitycultureformicrobiologicalcontaminations.Islet
samples are also analyzed for mycoplasma and endotoxin
content using FDA-approved methods. As a parameter of
islet function after transplantation, fasting serum C-peptide
levels were measured using a standard chemiluminescence
method.
3. Results
3.1. Patient Age, Body Weight, and Pancreas Size. Table 1
summarizes the age of the patients, their body weight at
the time of pancreatectomy and islet autotransplantation,
and the pancreatic organ weight. In all cases, pylorus-
preserving total pancreaticoduodenectomy was performed,
and the head, body, and tail of the pancreas were all sent to
the islet lab as sources of islet cells after back-table ﬂushing
(HTK solution) of the splenic and gastroduodenal arteries.
3.2. Islet Yield. Islet yield is expressed as the total islet
number (IEQ) per pancreas (Figure 1), islet number
(IEQ)/weight of digested pancreas (Figure 2), and islet
number (IEQ)/Kg body weight of the recipient (Figure 3(a)).
From a technical standpoint, IEQ is expressed per gram of
pancreas digested, and the density of the islets is indicative
of the eﬃciency of the extraction procedure. However,
for clinical purposes, the most indicative value is IEQ/Kg
body weight. Studies have shown that infusion of at least
2500IEQ/Kg is associated with an increased chance of
achieving satisfactory blood glucose control, while infusion
of ≥5000IEQ/Kg is very predictive of good metabolic
functionandeveninsulinindependence[18–21].Figure 3(b)
shows posttransplantation serum C-peptide levels relative to
this cohort of patients. The threshold of 2500IEQ/kg for
achieving satisfactory blood glucose control in recipients of
autologous islet transplantation [18] seems to apply also in
our cases, with the only exception of case no. 4. That is the
single case in which a suﬃciently high C-peptide level was
not obtained even with IEQ/kg greater than 7000.
3.3. Technical Management of the Isolation. The aim of the
isolation procedure is the recovery of the greatest number
of islets possible from the pancreatic organ; thus, care must
be taken to assure enough time for pancreatic digestion to
maximize islet yield, while at the same time not losing islets
to enzymatic or mechanical overdigestion. It is therefore
essential that the pancreatic organ is optimally perfused with
exogenous enzymes by intraductal injection of a solution
containing collagenases and neutral proteases. In all cases,
the pancreatic duct is located and cannulated using catheters
of appropriate size to ﬁt snugly in the duct (14 to 24G in
size). Sometimes in CP cases, the presence of calciﬁcations
renders the distribution of the enzyme in the pancreatic
parenchyma particularly diﬃcult. Consequently, distension4 Journal of Transplantation
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Figure 3:In(a)Isletyieldexpressedasisletequivalent(IEQ)numbersperkgofpatientbodyweight.In(b)SerumC-peptidelevels6months
after transplant. Case no. 9: Serum C-peptide levels 3 months post-transplant. NA: not available.
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Figure 4: At the end of the isolation, some tissue is left in the
digestion chamber. Of the undigested portion, only less than 20%
was glandular, with a prevalence of ﬁbrotic, calciﬁed, and ductal
tissue.
of the organ is less evident in pancreata with pancreatitis in
comparison with organs from healthy patients. In all of our
cases, however, a substantial increase in pancreatic volume
was achieved. This is indicative of good perfusion. At the
end of the isolation (enzymatic and mechanical) the tissue
left in the digestion chamber is weighed, and then by visual
inspection it is determined how much of what remains is
pancreatic tissue (i.e., islet containing tissue) and how much
is nonpancreatic, such as ductal tissue, ﬁbrotic tissue, and
blood vessels. The amount of nonpancreatic tissue is not
important for our purposes since islets cannot be obtained
from it, but the less undigested pancreatic tissue found, the
more eﬃcient we consider the digestion process. Figure 4
indicates the percent of tissue left undigested from each
organ treated. Our data indicates that more than 70% of the
initial tissue was digested, and of the remaining undigested
tissue just under 25% was estimated to be glandular (i.e., not
ductal, connective, or ﬁbrotic tissue). Considering that CP
substantiallyaﬀectstheanatomyofthepancreas,theseresults
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Figure 5: The pancreatic organ of young patients is subjected
ﬁrst to a stationary digestion characterized by prolonged infusion
of prewarmed collagenase-neutral protease solution. Mechanical
shaking is carried out after stationary digestion and limited in time
to avoid excessive breakage of islets embedded in exocrine tissue.
are rather encouraging. In fact, they are not signiﬁcantly
diﬀerent from the data obtained in isolations of organs from
healthy donors (data not shown).
3.4. Digestion Management. A combination of stationary
and mechanical digestions is usually necessary for eﬃcient
pancreatic digestion. Stationary digestion is deﬁned as the
time in which the pancreas is perfused with collagenases
in the Rajotte chamber. Mechanical digestion is considered
to begin when the pancreas is transferred into the Ricordi
chamber to the point in which the shaking, added to
break down the extracellular matrix, is stopped. In younger
donors, we have achieved better results by prolonging the
stationary digestion. Figure 5 shows the relative proportion
of stationary over mechanical digestion. As also described
by Balamurugan et al. [13], longer stationary digestion inJournal of Transplantation 5
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(when applied), the pancreatic cell pellet (comprised between 2.75
and 15mL) is suspended in medium containing human serum
albumin and bagged for infusion. Each bag contains a maximum
of 5mL of pellet tissue.
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Figure 7:Numberofcasesinwhichthepancreasprocurementﬂuid
and/or the islet cells showed positive microbiology.
younger donors is associated with a reduced yield of mantled
islets (i.e., nonendocrine cells surrounding the islets). While
a small mantle surrounding the islets may not be considered
detrimental and actually may confer protection [22], there is
general agreement that a thick mantle may prevent nutrients
from eﬃciently reaching the islet core, contributing to
necrosis and islet cell apoptosis.
3.5. Final Product. In our hands, the isolation yielded a
cell pellet that varied between 3 and 45mL in volume and
composed mainly of acinar cells and isolated islets. In most
cases, the cell pellet has a positive correlation with the
weight of the pancreas. Since a maximum of 15mL of cell
pellet is desirable for infusion (and even less in children
smaller than 75Kg), any cell pellet higher in volume requires
puriﬁcation to concentrate the islets in a lower volume by
reducing the amount of exocrine tissue. Puriﬁcation was
carried out in three cases: case 1, 5, and 8. The cell pellet was
reduced from 20mL to 4.5mL, from 45mL to 15mL, and
from 21mL to 11mL, respectively. Figure 6 indicates how
much cell pellet was obtained and infused and how many
infusion bags were delivered. Each bag can contain no more
than 5mL of cell pellet in 200mL infusion solution. In the
cases in which puriﬁcation was carried out, pellet size was
eﬃciently reduced to the standard volume for injection. It
was estimated that less than 15% of the ﬁnal islet mass was
lost due to the puriﬁcation process.
3.6. Microbiological Contamination. Samples of procure-
ment ﬂuid and islet cells taken to check sterility are
commonly found positive for bacterial contamination. The
presence of bacteria is probably secondary to the under-
lying disease, previous endoscopic procedures and, more
importantly, to the presence of the duodenum with the
specimen. Given the close relationship of the pancreas with
the duodenum, and the typical defective drainage of the
pancreaticjuices,contaminationfromintestinalﬂoraisoften
found in the procurement ﬂuid as well as the islets. Similar
incidence of bacterial contamination was also reported by
others [23].
Figure 7 and Table 2 show the results of the sterility
analysis and the isolated bacteria. Procurement ﬂuid was
quite commonly positive. In some cases, the isolate from the
procurement ﬂuid was also found within the islets. However,
in some few cases, the islets had diﬀerent isolates. Antibiotic
therapy has been eﬀective in controlling possible eﬀects of
the contaminations in vivo, and, in our experience, no cases
of postoperative infections were identiﬁed.
Mycoplasma and endotoxin levels are shown in Table 3.
4. Discussion
Chronic pancreatitis represents a very debilitating and
serious disorder, particularly in juveniles. The decision to
perform a total pancreatectomy is a weighty one considering
both short-term and long-term morbidity. Although it is
up to the gastroenterologist’s expertise to treat this disease
and to decide when all the available routes of intervention
have been exhausted, once surgical removal of the pancreas
becomes an option, it is important to consider islet cell
autotransplantation to reduce or eliminate a major source of
morbidity, diabetes. The surgical intervention is unchanged
whether autoislets are reinfused, regardless of the potential
residual endocrine function. If the islets are not given back
to the patient, they will be discarded. Rather than not using
the islets, even minimal endocrine function returned to
the patient, ethically and clinically justiﬁes the procedure
of islet isolation and autotransplantation [24]. We believe
that any additional risk, which is generally minimal to the
patient would be more than outweighed by the beneﬁt,
even considering limitations such as the quality and quantity
of the available islets, deteriorated as they are after the
prolonged inﬂammation of the organ, and the less than
ideal location of the infusion into the liver. Even if the islets
available for transplantation are limited in mass, it is proven
that a limited quantity of physiologically generated insulin
can be of great advantage for the patient. Administrations6 Journal of Transplantation
Table 2: Germ identiﬁcation.
Case no. Procurement ﬂuid Islet cells
1 Coagulase-negative staph no. 1, 2, 3 None
2N o n e C o a g u l a s e - n e g a t i v e s t a p h
3 Coagulase-negative staph Viridans Streptococcus
4 Enterobacter cloacae Enterobacter cloacae
Klebsiella pneumoniae Klebsiella pneumoniae
5 Enterobacter cloacae No. 1, 2 Enterobacter cloacae No. 1, 2
Viridans Streptococci
6 Escherichia coli Klebsiella oxytoca
7 Enterococcus faecium Enterococcus faecium
8 Micrococcus species None
Diphtheroids
9 Diphtheroids None
Klebsiella Pneumoniae
10 Peptostreptococcus Species None
Diphtheroids
Table 3: Endotoxins (EIU)/patient body Wt. (Kg), mycoplasma results.
C a s e n o . 123456789 1 0
Endotoxins/patient Wt. 0.63 N/A 5.88 N/A 3.48 0.54 0.70 0.88 0.67 1.22
Mycoplasma Neg. Neg. Neg. Neg. Neg. Neg. Neg. Neg. Neg. Neg.
of recombinant insulin could be completely avoided or the
quantity reduced.
Although the variables that clinically inﬂuence the eﬃ-
ciency of each transplant are high in numbers so that a direct
relationship between IEQ/kg and C-peptide production is
diﬃcult to demonstrate, we can agree that the previously
determined threshold of 2500–3000IEQ/kg is associated
with most successful clinical results [18].
Fromtheisletallotransplantationsetting,wealsolearned
that even minimal quantities of insulin and C-peptide
can reduce, respectively, hypoglycemia unawareness and its
frequently tragic consequences, as well as the blood vessel
atherosclerotic deterioration, principal cause of all typical
diabetes complications [25, 26]. Also, because it is an auto-
transplant, the absence of a need for immunosuppression
allows not only for a better engraftment of the islets, but also
for a potentially longer graft survival time than is observed
for the islets used in allotransplantation. The improved
survival is due in part to the absence of rejection, and in part
to the fact that the most used immunosuppressive regimens
include drugs that are toxic for the insulin-producing beta
cells [27].
The frequently less than lifelong survival of the graft
might not be due entirely to the stress that the isolation
protocol itself imposes on the islets, but also to the less
than ideal site of the infusion. The sinusoids of the liver,
while optimal to guarantee blood exposure to the islets and
a proper geographical location—being a part of the portal
system in which insulin is physiologically secreted—might
not be the most suited site for properly lodging them. It
is demonstrated that the islets transplanted into the liver
accumulateamyloiddepositsthat,notonlydamagetheliver’s
structure [28, 29], but also tends to physically isolate the
transplanted tissue, reducing its ability to obtain suﬃcient
oxygen and nutrients. While looking for more suitable sites
[30, 31], the present possibility of providing some diabetes-
free years or at least years of reduced insulin needs, still
supports the procedure of islet autotransplantation.
If, in many cases, the characteristics of the pancreas
are such that they do not allow for the harvest of a
suﬃciently large mass of islets to completely satisfy the
recipient’s insulin needs, a very sizeable improvement has
been obtained adapting our isolation procedure to better
digest the pancreas damaged by CP. We have found that
by optimizing the perfusion of collagenases through the
entire pancreas, by a technique in which we clamp any leaks,
allows for a more complete digestion. In addition, a longer
period of this stationary digestion is particularly beneﬁcial to
youngerpatientsinproducingalargeryieldofislets.Another
hallmark of our process is the ﬂexibility in the management
of the digestion, tailoring the amount of stationary and
mechanical digestion based on direct monitoring of the islets
released under the microscope rather than rigidly following
a ﬁxed standard of timing. The number of successful islet
autotransplants in young patients since we started this
protocol certainly supports our positive conclusions and
l e a d su st oc o n t i n u et os e a r c hf o ra l t e r n a t i v ew a y st ob e t t e r
digest the organ, better protect the islets during the isolation,
and ﬁnd a more suitable site to transplant the isolated islets.
We are currently testing drugs able to reduce the genera-
tion of dangerous reactive oxygen radicals during the organ
perfusion prior to islet isolation, during the isolation itself,
and even after transplantation, infusing the drug with the
isletsandintotherecipientintravenouslyoncethetransplantJournal of Transplantation 7
is completed [32, 33]. Better sites for allo- and possibly
autotransplantsarealsobeinginvestigated,suchasthegastric
submucosa,whichisaccessibleendoscopically[34].Through
thesamenoninvasiveroute,wecanalsoeasilyobtainbiopsies
useful to monitor the survival of the graft.
Some CP patients, because of family history or genetic
mutations, have a higher risk for developing pancreatic
cancer. A pancreatectomy will, of course, remove this risk.
However, the question remains if it is safe to isolate and
return the islets to these patients. Research into this question
is still relatively new; however, it appears that in these cases
an autotransplant of islets into the liver does not increase the
risk of the patient developing cancer [35]. The death of the
majority of the acinar cells during the isolation procedure
and the reduced quantity of ductal material remaining after
isolation may explain these positive results.
Autotransplantation has been demonstrated from the
results we have produced to date to be a procedure that is
worth continuing while investigating additional methods to
improve outcome.
5. Conclusions
Total pancreatectomy is the last resort for chronic pan-
creatitis. This treatment leads to surgical diabetes. The
decision to perform this drastic but sometimes only eﬀective
method of treatment is especially diﬃcult when dealing with
adolescents who face a lifetime of care for diabetes and its
complications.
Autotransplantation of pancreatic islets has shown the
ability to restore insulin function but was not considered to
be an eﬀective treatment for adolescents due to the diﬃculty
in producing enough islets. Our experience, however, has
shown that we are able to obtain a suﬃcient number of islets
that when transplanted back into patients even under the
age of 18, confers beneﬁts to their health and the chance to
achieve insulin independence.
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